To describe real-world prescribing patterns of sacubitril/valsartan (S/V) among patients with hypertension in Japan.
Approach:
Study Design: A retrospective cohort study using a nationwide Japanese electronic health record database from August 2020 to October 2023.
Patient Selection: Included adults with hypertension newly prescribed S/V, excluding those with heart failure.
Data Assessment: Evaluated concomitant antihypertensive medications, S/V dosing, and discontinuation patterns over 90 days.
Key Findings:
Ofthe9486painsmdg7yr503cvwlubk21zx
Interpretation:
S/V is predominantly prescribed in combination with CCBs, with a significant proportion receiving it as monotherapy. The findings indicate a need for further studies on the safety and efficacy of S/V-based combinations.
Limitations:
The study did not include patients with heart failure, limiting the generalizability of findings.
Limited guidance exists on optimizing first-line agents before S/V initiation.
Conclusion:
The study highlights the common use of S/V in combination with CCBs among hypertensive patients in Japan, emphasizing the need for further research on combination regimens.
